Compare
Whitehawk Therapeutics, Inc. vs Ovid Therapeutics Inc. vs Immunome Inc. vs Xenon Pharmaceuticals Inc.
| Latest fiscal year | Whitehawk Therapeutics, Inc. WHWK | Ovid Therapeutics Inc. OVID | Immunome Inc. IMNM | Xenon Pharmaceuticals Inc. XENE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $7.14M | $7.25M | $6.94M | $7.50M |
| Revenue growth (YoY) | -72.5% | n/m | -23.2% | n/a |
| Gross margin | 89.4% (computed) | n/a | n/a | n/a |
| Operating margin | n/m | -585.2% | n/m | n/m |
| Net margin | -288.3% | -240.1% | n/m | n/m |
| Net income | -$20.60M | -$17.41M | -$212.39M | -$345.91M |
| EPS (Diluted) | -$0.33 | n/a | -$2.43 | -$4.36 |
| Operating cash flow | -$97.43M | -$38.33M | -$190.92M | -$279.12M |
| Free cash flow | -$97.98M | -$38.33M | -$200.60M | -$279.92M |
| Cash & equivalents | $37.57M | $13.15M | $653.48M | $199.16M |
| Total assets | $150.83M | $150.93M | $683.19M | $633.16M |
| Total liabilities | $14.52M | $20.27M | $48.84M | $51.40M |
| Shareholders' equity | $136.31M | $130.66M | $634.34M | $581.76M |
| Return on year-end equity | -15.1% | -13.3% | -33.5% | -59.5% |
| Shares outstanding | 47.15M | 130.18M | 113.13M | 80.01M |
Revenue, most recent five fiscal years
| Fiscal year | Whitehawk Therapeutics, Inc. | Ovid Therapeutics Inc. | Immunome Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|---|---|
| Latest | $7.14M Ended 2025-12-31 | $7.25M Ended 2025-12-31 | $6.94M Ended 2025-12-31 | $7.50M Ended 2025-12-31 |
| 1 year earlier | $25.98M Ended 2024-12-31 | $566.0K Ended 2024-12-31 | $9.04M Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $24.35M Ended 2023-12-31 | $392.0K Ended 2023-12-31 | $14.02M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $15.22M Ended 2022-12-31 | $1.50M Ended 2022-12-31 | n/a | $9.43M Ended 2022-12-31 |
| 4 years earlier | $14.00M Ended 2021-12-31 | $208.38M Ended 2021-12-31 | n/a | $18.44M Ended 2021-12-31 |